Table 1. Summary of key components of each strategy.

	Chloroquine strategy	Primaquine strategy	Screening strategy
INITIAL VISIT
Treatment	Chloroquine given to all.	Chloroquine and supervised primaquine therapy (14 day) given to all. All individuals with severe G6PD deficiency stop primaquine therapy early. Females with intermediate G6PD deficiency who do not have severe hemolysis complete primaquine therapy.	Chloroquine and supervised primaquine therapy (14 day) given to those who test G6PD normal. Chloroquine and weekly primaquine given to those who test G6PD abnormal. Individuals with severe G6PD deficiency who are inadvertently given 14 day primaquine will stop therapy early. Females with intermediate G6PD deficiency who do not have severe hemolysis complete primaquine therapy.
RECURRENCES (all costs and DALYs are weighted by the proportion of severe cases)
Costs	Cost per recurrence.	Cost per recurrence. Supervised primaquine (14 day) for those who are G6PD normal.	Cost per recurrence. Includes G6PD RDT. Supervised primaquine (14 day) for those who are G6PD true normal. Supervised primaquine (8 weekly) for those who test G6PD abnormal and false normal.
Effects	All have the number of recurrences for chloroquine treatment.	G6PD abnormal individuals have the number of recurrences for chloroquine treatment. G6PD normal individuals have the number of recurrences for primaquine treatment.	Those who test G6PD false normal have the number of recurrences for chloroquine treatment. All other individuals have the number of recurrences for primaquine treatment.